ABL Diagnostics maps out AI push for molecular research and data security

By AI, Created 4:24 PM UTC, May 18, 2026, /AGP/ – ABL Diagnostics said it is building AI and machine learning into its molecular diagnostics and bioinformatics operations, with a focus on assay design, genomic interpretation and secure customer-owned data environments. The roadmap also centers on French HDS standards and EU and U.S. regulatory guidance as the company expands its global microbiology portfolio.

Why it matters: - ABL Diagnostics is tying AI to two pressures in molecular diagnostics: faster genomic analysis and tighter control of sensitive health data. - The approach could affect how laboratories use proprietary datasets without moving patient data outside their secure environment. - The company is also signaling that future AI tools will be built around regulatory and cybersecurity requirements from the start.

What happened: - ABL Diagnostics announced a strategic roadmap to integrate artificial intelligence and machine learning across its research and bioinformatics ecosystem. - The company said the effort is designed to improve assay design, genomic interpretation, productivity and workflow efficiency. - ABL Diagnostics is based in Woippy, France, and specializes in molecular diagnostics, bioinformatics and infectious disease solutions. - The company said the roadmap supports both internal R&D and operational processes.

The details: - ABL Diagnostics is using computational methods to improve its DeepChek® and UltraGene product portfolios. - The work focuses on automating genomic variability analysis and inclusivity assessments. - The company said the goal is to help molecular assays stay safe against rapidly evolving pathogens. - ABL Diagnostics said its AI infrastructure is built for machine learning in controlled, customer-owned environments. - The company said it does not seek to own patient data and instead provides computational engines for researchers to analyze their own datasets. - The “Privacy-by-Design” approach is intended to keep data inside the customer’s secure perimeter and prevent unauthorized model training. - ABL Diagnostics said it currently offers about forty DeepChek® assays for sequencing-based microbial genotyping and resistance analysis. - The company also said it has a comparable portfolio of UltraGene molecular assays based on Fast Track Diagnostics technology. - ABL Diagnostics is designing AI-enhanced modules to turn complex genomic data, including antimicrobial resistance markers and microbial variants, into scientific insights. - New AI-driven tools are intended for Research Use Only environments first. - The company said that allows verification, validation and performance benchmarking with laboratories, researchers and healthcare professionals before broader clinical use. - ABL Diagnostics said the AI roadmap is being built to follow EU IVDR regulations and U.S. FDA cybersecurity guidance. - The company said it is applying French HDS certification standards to its global infrastructure. - ABL Diagnostics described HDS as a health-data hosting framework that requires audits of healthcare-specific hosting and governance. - The company said the HDS baseline is meant to give customers worldwide the same level of security, transparency and data integrity expected under European standards for sensitive health information. - The company’s broader portfolio includes HIV drug-resistance testing, SARS-CoV-2, tuberculosis, hepatitis B and C detection, microbiome and taxonomy analysis, and other viral and bacterial assays. - ABL Diagnostics also offers real-time syndromic PCR tests, Nadis® patient medical records used in more than 200 hospitals in France, and MediaChek® clinical sample collection kits. - The company markets products globally through its own sales team and exclusive distributors on all continents. - ABL Diagnostics has also been marketing products and services from sister company CDL Pharma since the second half of 2025 under an intra-group strategy agreement. - The company is listed on compartment B of Euronext Paris under ticker ABLD and ISIN FR001400AHX6. - ABL Diagnostics said its molecular biology products generate recurring revenue and cover one of the largest microbiology application portfolios.

Between the lines: - The announcement places data sovereignty at the center of the company’s AI strategy, which is a key selling point for labs handling regulated or proprietary clinical data. - The emphasis on RUO-only deployment suggests ABL Diagnostics wants to prove performance before pushing AI deeper into clinical workflows. - Applying HDS standards globally is a notable signal that the company is trying to make European-grade hosting and governance a universal benchmark, not a regional one.

What’s next: - ABL Diagnostics is expected to keep building AI-enhanced bioinformatics modules and validate them in RUO settings first. - Broader clinical integration would likely depend on verification, benchmarking and compliance outcomes. - The company’s next competitive test will be whether its AI and security framework can translate into faster development cycles and stronger adoption across its assay portfolio.

The bottom line: - ABL Diagnostics is betting that secure, customer-controlled AI will become a core advantage in molecular diagnostics, not just a technical upgrade.